Drugs / Aticaprant
Trials 17
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT07615426 | Mar 2026 → Jun 2027 expected | schizophrenia | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 1 | NCT05387759 | May → Oct 2022 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT05197062 | Jan → Mar 2022 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT04791332 | Apr → Jul 2021 | — | Janssen Pharmaceutical K.K. | Completed | No outcome recorded |
| Phase 1 | NCT04185051 | Dec 2019 → Apr 2021 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT02218775 | Oct 2014 → Apr 2015 | anxiety disorder | Andrew Krystal | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT01232439 | Dec 2010 → Apr 2011 | alcohol dependence | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 25 trials · 2 met primary · 1 missed | ||||||
| Phase 2 | NCT03559192 | Jul 2018 → May 2020 | major depressive disorder | Janssen Research & Development, LLC | Completed | Met primary |
| Phase 2 | NCT02800928 | Jun 2016 → Jan 2018 | — | Yale University | Completed | No outcome recorded |
| Phase 2 | NCT02641028 | Dec 2015 → Sep 2016 | — | Janssen Research & Development, LLC | Completed | Missed primary |
| Phase 2 | NCT02218736 | Jun 2015 → Nov 2017 | anxiety disorder | Duke University | Completed | Met primary |
| Phase 2 | NCT01913535 | Sep 2013 → Jan 2016 | — | Massachusetts General Hospital | Terminated | No outcome recorded Stop: Enrollment |
| Phase 35 trials · 2 missed | ||||||
| Phase 3 | NCT06635135 | Sep 2024 → Apr 2025 | atypical depressive disorder, major depressive disorder | Janssen Research & Development, LLC | Terminated | No outcome recorded |
| Phase 3 | NCT06514742 | Jun 2024 → Apr 2025 | atypical depressive disorder, major depressive disorder | Janssen Research & Development, LLC | Terminated | No outcome recorded |
| Phase 3 | NCT05550532 | Dec 2022 → Nov 2024 | major depressive disorder | Janssen Research & Development, LLC | Completed | Missed primary |
| Phase 3 | NCT05518149 | Sep 2022 → Apr 2025 | major depressive disorder | Janssen Research & Development, LLC | Terminated | No outcome recorded |
| Phase 3 | NCT05455684 | Jun 2022 → Sep 2024 | atypical depressive disorder, major depressive disorder | Janssen Research & Development, LLC | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2025-03-06 | Janssen Research & Development, LLC | Results Johnson & Johnson Statement on VENTURA Program jnj.com ↗
Johnson & Johnson has made the decision to discontinue the Phase 3 VENTURA development program evaluating aticaprant as an adjunctive treatment for major depressive disorder (aMDD) due to insufficient efficacy in the target patient population. |
| 2017-05-01 | Avalo Therapeutics, Inc. | Results Cerecor Reports Encouraging Topline Data from a NIH Sponsored Proof-of-Concept Trial of CERC-501 in Treatment-Resistant Depression May 01, 2017 8:30am EDT avalotx.com ↗
CERC-501 showed a clinically meaningful 2.0-point difference from placebo on the Hamilton Rating Scale for Depression - 6 - items ("HAM-D-6"), change from baseline to 72 hours, which served as the primary efficacy measure. |
| 2016-12-05 | Avalo Therapeutics, Inc. | Results Cerecor Announces Top-Line Results from CERC-501 Phase 2 Study for Nicotine Withdrawal December 05, 2016 8:00am EST avalotx.com ↗
The trial did not meet its primary objective in nicotine withdrawal. |
| 2015-12-11 | Avalo Therapeutics, Inc. | Results Publication Reports Human Brain Penetration and Target Engagement of Cerecor’s Oral Kappa Opioid Receptor Antagonist, CERC-501 December 11, 2015 9:15am EST avalotx.com ↗
In this study of healthy volunteers, CERC-501 demonstrated reproducible penetration of the blood-brain barrier and target engagement, as shown through PET (positron emission tomography) imaging. |
All press releases naming this drug 9 releases
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Aticaprant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05518149 ↗ |
| Known as | CERC-501 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02218736 ↗ |
| Known as | JNJ-67953964 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04185051 ↗ |
| Known as | JNJ-67953964-AAA | ChEMBL registry synonym — accepted as the source's own label CHEMBL1921847 ↗ |
| Known as | JSPA-0658 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1921847 ↗ |
| Known as | LY2456302 | “Assessment of Brain Kappa Opioid Receptor Occupancy After Single Oral Doses of LY2456302 as Measured by PET With Radioligand LY2879788 in Healthy Subjects” NCT01232439 ↗ |
| Action | Inhibit | “opioid receptor kappa antagonist” NCT01232439 ↗1“Kappa opioid receptor antagonist” CHEMBL1921847 ↗ |
| Modality | Small molecule | — CHEMBL1921847 ↗ |
| Route | Oral | “administered orally” NCT01232439 ↗ |
| Target | OPRK1 | “Kappa opioid receptor antagonist” CHEMBL1921847 ↗ |